« Back
Home /
Gilteritinib

Gilteritinib

Item no.	HY-12432-5mg
Manufacturer	MedChem Express
CASRN	1254053-43-4
Amount	5 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Neuroscience Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Bone Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.84
Formula	C29H44N8O3
Citations	Acta Biomater. 2024 Sep 3:S1742-7061(24)00505-1. Biomed Pharmacother. 2023 Jun 29;165:115066. Biomed Pharmacother. 2024 Oct 28:180:117603. Blood Cancer J. 2022 Jan 11;12(1):5. Blood Cancer J. 2025 Mar 15;15(1):40. Cancer Cell Int. 2020 Jun 17;20:250. Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. Cancer Discov. 2023 Apr 3;CD-22-0411. Cancer Lett. 2024 May 3:216933. Cancer Res Commun. 2024 Jan 29. Cancers. 2020 Aug 19;12(9):2341. Cancers. 2020 Jun 14;12(6):1574. Cell Biol Toxicol. 2024 Nov 28;40(1):105. Cell Rep Med. 2024 Jul 16;5(7):101645. Cell Rep. 2024 Sep 25:114774. Comput Biol Med. 2023 Dec 21, 107889. Department of Pharmacology & Toxicology. 2020 Jul. Front Pharmacol. 2021 Mar 8;12:644342. Haematologica. 2018 Nov;103(11):1862-1872. J Control Release. 2024 Feb 15:367:821-836. J Oncol. 21 Sep 2021. Mol Cancer Res. 2021 Oct 11. Mol Pharmacol. April 5, 2022. Mol Syst Biol. 2023 Dec 18. Nat Cancer. 2024 May 30. Polymers. 2024 Jan 12, 16(2), 225. Research Square Preprint. 2023 Dec 6. Sci Adv. 2022 Sep 16;8(37):eabp9005. Sci Rep. 2021 Mar 11;11(1):5715. Science. 2017 Dec 1;358(6367):eaan4368. Separations. 2023 Apr 25, 10(5), 278. Target Oncol. 2022 Oct 6. Blood Cancer Discov. 2022 Mar 4;bloodcandisc.0163.2021. Eur J Med Chem. 2022 Jul 5;237:114356. [1]ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ASCO Annual Meeting. [2]Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565.
Smiles	NC(C1=NC(CC)=C(NC2CCOCC2)N=C1NC3=CC(OC)=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ASP2215
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	FLT3; TAM Receptor
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, stored under nitrogen)
Molecular Weight	552.71
Product Description	Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 2 mg/mL (ultrasonic)\|Ethanol : 100 mg/mL (ultrasonic; adjust pH to 2 with HCl)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Isoform	Axl
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12432-5mg-safety-datasheet.pdf